Acute shock induced by antigen vaccination in NOD mice

Diabetes

Volumn 52, Issue 2, 2003, Pages 335-341

  Overbergh, Lut ^a   Decallonne, Brigitte ^a   Branisteanu, Dumitru D ^b   Valckx, Dirk ^a   Kasran, Ahmad ^a   Bouillon, Roger ^a   Mathieu, Chantal ^a,c  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c LEGENDO   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

APAFANT; AUTOANTIGEN; CALCITRIOL; DEXAMETHASONE; IMMUNOGLOBULIN E; LYSOZYME; MESSENGER RNA; THROMBOCYTE ACTIVATING FACTOR RECEPTOR;

ANAPHYLACTIC SHOCK; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; FEMALE; IMMUNOGLOBULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE DIFFERENTIATION; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; SHOCK; TH1 CELL; TH2 CELL; VACCINATION;

ANIMALS; AUTOANTIGENS; CALCITRIOL; CHICKENS; DEXAMETHASONE; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; DNA PRIMERS; IMMUNOGLOBULIN E; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED NOD; MURAMIDASE; PLATELET MEMBRANE GLYCOPROTEINS; RECEPTORS, CELL SURFACE; RECEPTORS, G-PROTEIN-COUPLED; SHOCK; T-LYMPHOCYTES, HELPER-INDUCER; TH2 CELLS; VACCINES;

EID: 0037312839     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.52.2.335     Document Type: Article

References (46)

1. Yoon JW, Jun HS: Cellular and molecular pathogenic mechanisms of insulin-dependent diabetes mellitus. Ann N Y Acad Sci 928:200-211, 2001
2. Adorini L, Gregori S, Harrison LC: Understanding autoimmune diabetes: insights from mouse models. Trends Mol Med 8:31-38, 2002
3. Rabinovitch A: An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus. Diabetes Metab Rev 14:129-151, 1998
4. Wong FS, Janeway CA Jr: Insulin-dependent diabetes mellitus and its animal models. Curr Opin Immunol 11:643-647, 1999
5. Casares S, Brumeanu TD: Insights into the pathogenesis of type 1 diabetes: a hint for novel immunospecific therapies. Curr Mol Med 1:357-378, 2001
6. Kundig TM, Bachmann MF, Ohashi PS, Pircher H, Hengartner H, Zinkernagel RM: On T cell memory: arguments for antigen dependence. Immunol Rev 150:63-90, 1996
7. Foucras G, Gallard A, Coureau C, Kanellopoulos JM, Guery JC: Chronic soluble antigen sensitization primes a unique memory/effector T cell repertoire associated with Th2 phenotype acquisition in vivo. J Immunol 168:179-187, 2002
8. Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR: β-Cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind phase II trial. Lancet 358:1749-1753, 2002
9. Ramiya VK, Lan MS, Wasserfall CH, Notkins AL, Maclaren NK: Immunization therapies in the prevention of diabetes. J Autoimmun 10:287-292, 1997
10. Willenborg DO, Staykova MA: Approaches to the treatment of central nervous system autoimmune disease using specific neuroantigen. Immunol Cell Biol 76:91-103, 1998
11. Pedotti R, Mitchell D, Wedemeyer J, Karpuj M, Chabas D, Hattab EM, Tsai M, Galli SJ, Steinman L: An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide. Nat Immunol 2:216-222, 2001
12. Kappos L, Comi G, Panitch H, Oger J, Antel J, Cordon P, Steinman L, The Altered Peptide Ligand in Relapsing MS Study Group: Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. Nat Med 6:1176-1182, 2000
13. Harada M, Nagata M, Takeuchi M, Makino S, Aburahi S: High susceptibility of cataract Shionogi (CTS) mice to passive anaphylactic shock mediated by allogeneic IgE and IgG1 monoclonal antibodies. Immunol Invest 20:305-315, 1991
14. Hurtenbach U, Lier E, Adorini L, Nagy ZA: Prevention of autoimmune diabetes in non-obese diabetic mice by treatment with a class II major histocompatibility compex-blocking peptide. J Exp Med 177:1499-1504, 1993
15. Pozilli P, Signore A, Williams AJ, Beales P: NOD mouse colonies around the world: recent facts and figures. Immunol Today 14:193-196, 1993
16. Giulietti A, Overbergh L, Valckx D, Decallonne B, Bouillon R, Mathieu C: An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods 25:386-401, 2001
17. Singh VK, Mehrotra S, Agarwal SS: The paradigm of Th1 and Th2 cytokines: its relevance to autoimmunity and allergy. Immunol Res 20:147-161, 1999
18. Parish NM, Hutchings PR, O'Reilly L, Quartey-Papaflo R, Healey D, Ozegbe P, Cooke A: Tolerance induction as a therapeutic strategy for the control of autoimmune endocrine disease in mouse models. Immunol Rev 144:269-300, 1995
19. Bach JF, Chatenoud L: Tolerance to islet autoantigens in type 1 diabetes. Annu Rev Immunol 19:131-161, 2001
20. Simone EA, Wegmann DR, Eisenbarth GS: Immunologic "vaccination" for the prevention of autoimmune diabetes (type 1A). Diabetes Care 22 (Suppl. 2):B7-B15, 1999
21. Silverstein AM: Autoimmunity versus horror autotoxicus: the struggle for recognition. Nat Immunol 2:279-281, 2001
22. Broide DH: Molecular and cellular mechanisms of allergic disease. J Allergy Clin Immunol 108:S65-S71, 2001
23. Kay AB: Allergy and allergic diseases: first of two parts. N Engl J Med 344:30-37, 2001
24. Wiendl H, Neuhaus O, Kappos L, Hohlfeld R: Multiple sclerosis: current view of failed and discontinued clinical trials of drug treatment. Nervenarzt 71:597-610, 2000
25. Hartemann AH, Richard MF, Boitard C: Absence of significant Th2 response in diabetes-prone non-obese diabetic (NOD) mice. Clin Exp Immunol 116:225-230, 1999
26. Schloot NC, Hanifi-Moghaddam P, Goebel C, Shatavi SV, Flohe S, Kolb H, Rothe H: Serum IFN-gamma and IL-10: levels are associated with disease progression in non-obese diabetic mice. Diabetes Metab Res Rev 18:64-70, 2002
27. Mathieu C, Adorini L: The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol Me 8:174-179, 2002
28. Mathieu C, Laureys J, Sobis H, Vandeputte M, Waer M, Bouillon R: 1,25-Dihydroxyvitamin D3 prevents insulitis in NOD mice. Diabetes 41:1491-1495, 1992
29. Branisteanu DD, Waer M, Sobis H, Marcelis S, Vandeputte M, Bouillon R: Prevention of murine experimental allergic encephalomyelitis: cooperative effects of cyclosporine and 1 alpha, 25-(OH)2D3. J Neuroimmunol 6:151-160, 1995
30. Hayashi T, Hasegawa K, Nakai S, Hamachi T, Adachi Y, Yamauchi Y, Maeda K: Bronchial lesions of the late asthmatic response in Balb/c and C57BL/6 mice. J Comp Pathol 125:208-213, 2001
31. Strid J, Lopes L, Marcinkiewicz J, Petrovska L, Nowak B, Chain BM, Lund T: A defect in bone marrow derived dendritic cell maturation in the nonobese diabetic mouse. Clin Exp Immunol 123:375-381, 2001
32. Piganelli JD, Martin T, Haskins K: Splenic macrophages from the NOD mouse are defective in the ability to present antigen. Diabetes 47:1212-1218, 1998
33. Overbergh L, Decallonne B, Waer M, Rutgeerts O, Valckx D, Casteels KM, Laureys J, Bouillon R, Mathieu C: 1alpha,25-dihydroxyvitamin D3 induces an autoantigen-specific T-helper 1/T-helper 2 immune shift in NOD mice immunized with GAD65 (p524-543). Diabetes 49:1301-1307, 2000
34. Shultz L, Schweitzer P, Christianson S, Gott B, Schweitzer I, Tennent B, McKenna S, Mobraaten L, Rajan T, Greiner D, Leiter E: Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol 154:180-191, 1995
35. Zurawski G, de Vries JE: Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol Today 15:19-26, 1994
36. Brombacher F: The role of interleukin-13 in infectious diseases and allergy. Bioessays 22:646-656, 2000
37. Fallon PG, Emson CL, Smith P, McKenzie AN: IL-13 overexpression predisposes to anaphylaxis following antigen sensitization. J Immunol 166:2712-2716, 2001
38. Corry DB, Kheradmand F: Induction and regulation of the IgE response (Review Article) Nature 402 (Suppl. 6760):B18-B23, 1999
39. Ayala A, Chaudry IH: Platelet activating factor and its role in trauma, shock, and sepsis. New Horiz 4:265-275, 1996
40. Snyder F: Platelet-activating factor and its analogs: metabolic pathways and related intracellular processes. Biochim Biophys Acta 1254:231-249, 1995
41. Chen SF, Ruan YJ: 1 alpha,25-Dihydroxyvitamin D3 decreases scalding-and platelet-activating factor-induced high vascular permeability and tissue oedema. Pharmacol Toxicol 76:365-367, 1995
42. Narahara H, Miyakawa I, Johnston JM: The inhibitory effect of 1,25-dihydroxyvitamin D3 on the secretion of platelet-activating factor acetylhydrolase by human decidual macrophages. J Clin Endocrinol Metab 80:3121-3126, 1995
43. Muller E, Dupuis G, Turcotte S, Rola-Pleszczynski M: Human PAF receptor gene expression: induction during HL-60 cell differentiation. Biochem Biophys Res Commun 181:1580-1586, 1991
44. Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM: Platelet-activating factor acetylhydrolases. J Biol Chem 272:17895-17898, 1997
45. Strait RT, Morris SC, Yang M, Qu XW, Finkelman FD: Pathways of anaphylaxis in the mouse. J Allergy Clin Immunol 109:658-668, 2002
46. Friday RP, Trucco M, Pietropaolo M: Genetics of type 1 diabetes mellitus. Diabetes Nutr Metab 12:3-26, 1999